Indoleamine 2,3-dioxygenase/IDO Antibody (700826) [Alexa Fluor™ Plus 647]

• Reactivity: Hu
• Clone: 700826
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 647

Indoleamine 2,3-dioxygenase/IDO Antibody (700826) [Alexa Fluor™ Plus 647] Summary

• Specificity: Detects human Indoleamine 2,3‑dioxygenase/IDO in direct ELISAs.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Indoleamine 2,3-dioxygenase/IDO Antibody (700826) [Alexa Fluor™ Plus 647]

• 3dioxygenase
• EC 1.13.11.52
• IDO
• IDO1
• IDOIDO-1
• INDO
• INDOindole 2,3-dioxygenase
• Indoleamine 2
• indoleamine 2,3-dioxygenase 1
• Indoleamine 2,3-dioxygenase
• indoleamine-pyrrole 2,3 dioxygenase
• Indoleamine-pyrrole 2,3-dioxygenase

Background

Indoleamine 2,3-dioxygenase (IDO) is a heme-containing intracellular dioxygenase catalyzing the degradation of the essential amino acid L-tryptophan to N-formyl-kynurenine (1). This degradation is the first and rate-limiting step of the L-kynurenine pathway (2). IDO is widely expressed in dendritic cells, macrophages, microglia, eosinophils, fibroblasts, endothelial cells, and most tumor cells. In immune cells, its expression is mainly induced by cytokines such as IFN-gamma , IFN-alpha , IFN-beta , and IL‑10. IDO has an antimicrobial function due to its decreasing the availability of the essential amino acid tryptophan in inflammatory environments (3). Recent studies have demonstrated that IDO induces immunosuppression during infection, pregnancy, transplantation, autoimmunity, and neoplasia (3-5).

1. Lewis-Ballester, A. et al. (2009) Proc. Natl. Acad. Sci. USA. 106:17371.
2. Costantino, G. (2009) Expert Opin. Ther. Targets 13:247.
3. Xu, H. et al. (2008) Immunol. Lett. 121:1.
4. Lob, S. et al. (2009) Nat. Rev. Cancer 9:445.
5. Curti, A. et al. (2009) Blood 113:2394.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.